Mengmeng Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mengmeng Li has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Jingyi Li
Department of Dermatology and Venereology, West China Hospital Sichuan University Chengdu China
5 shared publications - Qingfeng Liu
Department of Dermatology and Venereology, West China Hospital of Sichuan University, No.37 Guo Xue Lane, Chengdu 610041, China
4 shared publications - Wei Li
Department of Dermatology & Venerology, Rare Diseases Center, West China Hospital Sichuan University Chengdu Sichuan China
4 shared publications Xingli Zhou
Department of Dermatology West China Hospital, Sichuan University Chengdu China
3 shared publicationsYue Xiao
Department of Dermatology West China Hospital, Sichuan University Chengdu China
3 shared publications- Chun He
Department of Dermatology and Venereology, West China Hospital of Sichuan University, No.37 Guo Xue Lane, Chengdu 610041, China
2 shared publications
Latest Publications
- Open Access
Exploring the Relationships Between Residential Green Spaces and Childhood Allergic Diseases in Chengdu, China
Studies on the association between green spaces and childhood allergic diseases are limited and have yielded inconsistent results across different regions. Furthermore, this relationship remains underexplored in Chengdu, China. In this study, we aimed to investigate the association between the residential greening rate, Normalized Difference Vegetation Index (NDVI), proportion of allergenic plants (proportion of allergenic woody plants, proportion of allergenic herbaceous plants), the closeness-to-nature characteristics of children’s playgrounds, and childhood allergic diseases in Chengdu. Seven representative neighborhoods were selected based on a 2018 database of pediatric patients from West China Hospital of Sichuan University. Through questionnaires in 2025, data on allergic diseases (e.g., atopic dermatitis and allergic rhinitis) were collected for 210 children aged 0–6 years. Logistic regression models were employed to analyze the data. The results indicate that in the overall sample, residential greening rate, NDVI, proportion of allergenic plants and closeness-to-nature characteristics of children’s playgrounds showed no significant association with allergic diseases. However, subgroup analyses revealed that greening rate was positively associated with allergy risk among children aged 0–3 years, whereas the proportion of allergenic woody plants was negatively associated with allergy risk in this age group; residential NDVI was significantly negatively associated with allergy risk in low-to-medium-housing-price neighborhoods (2), but positively associated in high-housing-price neighborhoods (≥19,000 CNY/m2); the proportion of allergenic herbaceous plants was significantly negatively associated with allergy risk in children only in high-housing-price neighborhoods. The presence of children’s playgrounds, accessibility of natural elements, integration of sites and facilities into the landscape, and use of natural materials in playgrounds and facilities showed a negative trend with allergy risk in low-to-medium-housing-price neighborhoods; the integration of sites and facilities into the landscape was significantly positively associated with allergy risk in high-rise neighborhoods. Collectively, these associations vary based on individual and neighborhood characteristics. Targeted green space planning and design interventions should be context-specific, synergistically optimizing vegetation coverage and plant composition, while enhancing the closeness-to-nature characteristics of children’s playgrounds within neighborhoods. Our results provide empirical evidence that may offer insights into the development of healthy and child-friendly cities.
Open AccessExploring the Relationships Between Residential Green Spaces and Childhood Allergic Diseases in Chengdu, China
Studies on the association between green spaces and childhood allergic diseases are limited and have yielded inconsistent results across different regions. Furthermore, this relationship remains underexplored in Chengdu, China. In this study, we aimed to investigate the association between the residential greening rate, Normalized Difference Vegetation Index (NDVI), proportion of allergenic plants (proportion of allergenic woody plants, proportion of allergenic herbaceous plants), the closeness-to-nature characteristics of children’s playgrounds, and childhood allergic diseases in Chengdu. Seven representative neighborhoods were selected based on a 2018 database of pediatric patients from West China Hospital of Sichuan University. Through questionnaires in 2025, data on allergic diseases (e.g., atopic dermatitis and allergic rhinitis) were collected for 210 children aged 0–6 years. Logistic regression models were employed to analyze the data. The results indicate that in the overall sample, residential greening rate, NDVI, proportion of allergenic plants and closeness-to-nature characteristics of children’s playgrounds showed no significant association with allergic diseases. However, subgroup analyses revealed that greening rate was positively associated with allergy risk among children aged 0–3 years, whereas the proportion of allergenic woody plants was negatively associated with allergy risk in this age group; residential NDVI was significantly negatively associated with allergy risk in low-to-medium-housing-price neighborhoods (2), but positively associated in high-housing-price neighborhoods (≥19,000 CNY/m2); the proportion of allergenic herbaceous plants was significantly negatively associated with allergy risk in children only in high-housing-price neighborhoods. The presence of children’s playgrounds, accessibility of natural elements, integration of sites and facilities into the landscape, and use of natural materials in playgrounds and facilities showed a negative trend with allergy risk in low-to-medium-housing-price neighborhoods; the integration of sites and facilities into the landscape was significantly positively associated with allergy risk in high-rise neighborhoods. Collectively, these associations vary based on individual and neighborhood characteristics. Targeted green space planning and design interventions should be context-specific, synergistically optimizing vegetation coverage and plant composition, while enhancing the closeness-to-nature characteristics of children’s playgrounds within neighborhoods. Our results provide empirical evidence that may offer insights into the development of healthy and child-friendly cities.
- Open Access
- 27 April 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (9) , 3015
Construction and Evaluation of an Artificial Intelligence Assistant Decision-Making System Focused on the Treat-to-Target Framework and Full Process Management for Atopic Dermatitis: Study Protocol for a Randomized Controlled Trial
Background/Objectives: Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by recurrent rashes and itching, which seriously affects the quality of life of patients and brings a heavy economic burden to society. The treat-to-target (T2T) strategy was proposed to guide optimal use of systemic therapies in patients with moderate to severe AD, and patients’ adherence is emphasized along with combined evaluation from both health providers and patients. While effective treatments for AD are available, non-adherence of treatment is common in clinical practice due to the patients’ unawareness of self-evaluation and lack of concern about the specific follow-up time points in clinics, which leads to the treatment failure and repeated relapse of AD. Methods: This project consists of three parts. First, an artificial intelligence (AI) model for diagnosis and severity grading of AD based on deep learning will be trained. Second, an AI assistant decision-making system (AIADMS) in the form of an app will be developed. Third, we design a prospective, randomized controlled trial to test the hypothesis that the AIADMS with implementation of the T2T could help control the disease progression and improve the clinical outcomes. Results: A total of 232 participants diagnosed with moderate to severe AD will be included and allocated into the app group or the control group. In the app group, participants will be assisted in using the app during the process of management and follow-up at the scheduled time points, including 2 weeks, 4 weeks, 8 weeks, 12 weeks, 6 months, and 12 months after treatment. In the control group, the diagnosis, treatment, and follow-up of participants will be carried out according to the current routine on a face-to-face basis. The primary outcome is the overall efficiency rate of treating objectives including PP-NRS, EASI, SCORAD, POEM, and DLQI at 12 weeks after treatment, which is calculated as the “Total number of participants with effective treatment of 5 treating objectives/total number of participants *100%”. Spss20.0 software will be used to analyze the data according to the principle of intent to treat. Trial Registration: The protocol was registered at the National Institutes of Health Clinical Trials Registry with the trial registration number NCT06362629 on 11 April 2024. Conclusions: This study aims to improve AD management by integrating advanced technology, patient engagement, and clinician oversight through AIADMS app to achieve treat-to-target (T2T) goals for effective and safe long-term control.
- 27 April 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (9) , 3015
Open AccessConstruction and Evaluation of an Artificial Intelligence Assistant Decision-Making System Focused on the Treat-to-Target Framework and Full Process Management for Atopic Dermatitis: Study Protocol for a Randomized Controlled Trial
Background/Objectives: Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by recurrent rashes and itching, which seriously affects the quality of life of patients and brings a heavy economic burden to society. The treat-to-target (T2T) strategy was proposed to guide optimal use of systemic therapies in patients with moderate to severe AD, and patients’ adherence is emphasized along with combined evaluation from both health providers and patients. While effective treatments for AD are available, non-adherence of treatment is common in clinical practice due to the patients’ unawareness of self-evaluation and lack of concern about the specific follow-up time points in clinics, which leads to the treatment failure and repeated relapse of AD. Methods: This project consists of three parts. First, an artificial intelligence (AI) model for diagnosis and severity grading of AD based on deep learning will be trained. Second, an AI assistant decision-making system (AIADMS) in the form of an app will be developed. Third, we design a prospective, randomized controlled trial to test the hypothesis that the AIADMS with implementation of the T2T could help control the disease progression and improve the clinical outcomes. Results: A total of 232 participants diagnosed with moderate to severe AD will be included and allocated into the app group or the control group. In the app group, participants will be assisted in using the app during the process of management and follow-up at the scheduled time points, including 2 weeks, 4 weeks, 8 weeks, 12 weeks, 6 months, and 12 months after treatment. In the control group, the diagnosis, treatment, and follow-up of participants will be carried out according to the current routine on a face-to-face basis. The primary outcome is the overall efficiency rate of treating objectives including PP-NRS, EASI, SCORAD, POEM, and DLQI at 12 weeks after treatment, which is calculated as the “Total number of participants with effective treatment of 5 treating objectives/total number of participants *100%”. Spss20.0 software will be used to analyze the data according to the principle of intent to treat. Trial Registration: The protocol was registered at the National Institutes of Health Clinical Trials Registry with the trial registration number NCT06362629 on 11 April 2024. Conclusions: This study aims to improve AD management by integrating advanced technology, patient engagement, and clinician oversight through AIADMS app to achieve treat-to-target (T2T) goals for effective and safe long-term control.
- 8 October 2024
- Published by Wiley in The Journal of Dermatology
- Vol. 52 (3) , 526-530
A case of peeling skin syndrome type 1 with novel CDSN gene variation successfully treated with upadacitinib
Peeling skin syndrome type 1 (PSS1) is an autosomal recessive genodermatosis caused by the CDSN gene loss‐of‐function mutation and characterized by widespread superficial skin peeling and erythroderma with unbearable pruritus. Because of its ultra‐rarity and unclear mechanism, this rare disease has no established treatment regimen. Herein, we reported a Chinese woman who presented with congenital generalized pruritic erythroderma and exfoliation, notable for significantly elevated IgE levels. The whole exome sequencing identified an unpublished homozygous variant (c.295C>T, p.Gln99*) in the CDSN gene, confirming the diagnosis of PSS1. Immunohistochemistry analysis of the affected skin confirmed the lack of corneodesmosin expression, revealed the overexpression of T helper 2 (Th2)–related cytokines harboring interleukin (IL) 4 and IL‐13. After Janus kinase 1 (JAK1) inhibitor upadacitinib administration, both the patient's skin rashes and itching symptoms were significantly alleviated. Our work expanded the PSS1‐related CDSN gene mutation spectrums, substantiated the hypothesis regarding the overexpression of Th2‐related cytokines, and uncovered the important role of JAK1 underlying PSS1. JAK1 signaling may dominate the pathogenesis in PSS1 and represent a potential therapeutic target.
- 8 October 2024
- Published by Wiley in The Journal of Dermatology
- Vol. 52 (3) , 526-530
A case of peeling skin syndrome type 1 with novel CDSN gene variation successfully treated with upadacitinib
Peeling skin syndrome type 1 (PSS1) is an autosomal recessive genodermatosis caused by the CDSN gene loss‐of‐function mutation and characterized by widespread superficial skin peeling and erythroderma with unbearable pruritus. Because of its ultra‐rarity and unclear mechanism, this rare disease has no established treatment regimen. Herein, we reported a Chinese woman who presented with congenital generalized pruritic erythroderma and exfoliation, notable for significantly elevated IgE levels. The whole exome sequencing identified an unpublished homozygous variant (c.295C>T, p.Gln99*) in the CDSN gene, confirming the diagnosis of PSS1. Immunohistochemistry analysis of the affected skin confirmed the lack of corneodesmosin expression, revealed the overexpression of T helper 2 (Th2)–related cytokines harboring interleukin (IL) 4 and IL‐13. After Janus kinase 1 (JAK1) inhibitor upadacitinib administration, both the patient's skin rashes and itching symptoms were significantly alleviated. Our work expanded the PSS1‐related CDSN gene mutation spectrums, substantiated the hypothesis regarding the overexpression of Th2‐related cytokines, and uncovered the important role of JAK1 underlying PSS1. JAK1 signaling may dominate the pathogenesis in PSS1 and represent a potential therapeutic target.
- 1 September 2024
- Published by SAGE Publications in Dermatitis®
- Vol. 35 (5) , 533-535
Clinical and Pathological Features of Concomitant Atopic Dermatitis and Psoriasis: A Single-Center Retrospective Study in China
- 1 September 2024
- Published by SAGE Publications in Dermatitis®
- Vol. 35 (5) , 533-535
Clinical and Pathological Features of Concomitant Atopic Dermatitis and Psoriasis: A Single-Center Retrospective Study in China
- 1 September 2024
- Published by SAGE Publications in Dermatitis®
- Vol. 35 (5) , 541-543
A 42-Year Delay in Diagnosing Hereditary Angioedema: A Case Report
- 1 September 2024
- Published by SAGE Publications in Dermatitis®
- Vol. 35 (5) , 541-543
A 42-Year Delay in Diagnosing Hereditary Angioedema: A Case Report
- 1 December 2022
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 47 (12) , 2305
Comment on: ‘Eczematous drug eruption in patients with psoriasis under anti-interleukin-17A: does interleukin-22 play a key role?’
- 1 December 2022
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 47 (12) , 2305
Comment on: ‘Eczematous drug eruption in patients with psoriasis under anti-interleukin-17A: does interleukin-22 play a key role?’
- Open Access
- 26 September 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (19) , 11371
Calcium-Based Antimicrobial Peptide Compounds Attenuate DNFB-Induced Atopic Dermatitis-Like Skin Lesions via Th-Cells in BALB/c Mice
Atopic dermatitis (AD) is a chronic and recurrent inflammatory skin disease, characterized by severe itching and recurrent skin lesions. We hypothesized that a novel treatment involving calcium-based antimicrobial peptide compounds (CAPCS), a combination of natural calcium extracted from marine shellfish, and a variety of antimicrobial peptides, may be beneficial for AD. We established a dinitrofluorobenzene (DNFB)-induced AD model in BALB/c mice to test our hypothesis. We observed mouse behavior and conducted histopathological and immunohistochemical analyses on skin lesions before and after CAPCS treatment. We also characterized the changes in the levels of cytokines, inflammatory mediators, and Toll-like receptors (TLRs) in plasma and skin lesions. The results showed that (i) topical application of CAPCS ameliorated AD-like skin lesions and reduced scratching behavior in BALB/c mice; (ii) CAPCS suppressed infiltration of inflammatory cells and inhibited the expression of inflammatory cytokines in AD-like skin lesions; (iii) CAPCS reduced plasma levels of inflammatory cytokines; and (iv) CAPCS inhibited TLR2 and TLR4 protein expression in skin lesions. Topical application of CAPCS exhibits a therapeutic effect on AD by inhibiting inflammatory immune responses via recruiting helper T cells and engaging the TLR2 and TLR4 signaling pathways. Therefore, CAPCS may be useful for the treatment of AD.
- 26 September 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (19) , 11371
Open AccessCalcium-Based Antimicrobial Peptide Compounds Attenuate DNFB-Induced Atopic Dermatitis-Like Skin Lesions via Th-Cells in BALB/c Mice
Atopic dermatitis (AD) is a chronic and recurrent inflammatory skin disease, characterized by severe itching and recurrent skin lesions. We hypothesized that a novel treatment involving calcium-based antimicrobial peptide compounds (CAPCS), a combination of natural calcium extracted from marine shellfish, and a variety of antimicrobial peptides, may be beneficial for AD. We established a dinitrofluorobenzene (DNFB)-induced AD model in BALB/c mice to test our hypothesis. We observed mouse behavior and conducted histopathological and immunohistochemical analyses on skin lesions before and after CAPCS treatment. We also characterized the changes in the levels of cytokines, inflammatory mediators, and Toll-like receptors (TLRs) in plasma and skin lesions. The results showed that (i) topical application of CAPCS ameliorated AD-like skin lesions and reduced scratching behavior in BALB/c mice; (ii) CAPCS suppressed infiltration of inflammatory cells and inhibited the expression of inflammatory cytokines in AD-like skin lesions; (iii) CAPCS reduced plasma levels of inflammatory cytokines; and (iv) CAPCS inhibited TLR2 and TLR4 protein expression in skin lesions. Topical application of CAPCS exhibits a therapeutic effect on AD by inhibiting inflammatory immune responses via recruiting helper T cells and engaging the TLR2 and TLR4 signaling pathways. Therefore, CAPCS may be useful for the treatment of AD.
- 4 August 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (1) , 67-77.e15
GWAS of Chronic Spontaneous Urticaria Reveals Genetic Overlap with Autoimmune Diseases, Not Atopic Diseases
- 4 August 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (1) , 67-77.e15
GWAS of Chronic Spontaneous Urticaria Reveals Genetic Overlap with Autoimmune Diseases, Not Atopic Diseases
- 31 July 2022
- Published by Wiley in Dermatologic Therapy
- Vol. 35 (9) , e15724
Refractory cutaneous lichen amyloidosis coexisting with atopic dermatitis responds to the Janus Kinase inhibitor baricitinib
- 31 July 2022
- Published by Wiley in Dermatologic Therapy
- Vol. 35 (9) , e15724
Refractory cutaneous lichen amyloidosis coexisting with atopic dermatitis responds to the Janus Kinase inhibitor baricitinib
- 2 June 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 142 (11) , 2998-3008.e5
Plasma-Derived Exosomes in Chronic Spontaneous Urticaria Induce the Production of Mediators by Human Mast Cells
- 2 June 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 142 (11) , 2998-3008.e5
Plasma-Derived Exosomes in Chronic Spontaneous Urticaria Induce the Production of Mediators by Human Mast Cells